This bill amends Florida Statutes to regulate xylazine and other synthetic substances more stringently. It specifies that xylazine is excluded from Schedule I controlled substances if it is FDA-approved for specific animal uses, but its manufacture, distribution, and sale for human use remain regulated. The bill introduces criminal penalties for the sale, manufacture, delivery, or possession with intent to sell xylazine, establishing a mandatory minimum term of imprisonment. It also creates a new offense for trafficking in xylazine, with penalties and fines that vary based on the quantity involved, aiming to address concerns about its misuse while allowing for legitimate veterinary applications.

Additionally, the bill expands the list of controlled substances to include various synthetic cannabinoids and substituted cathinones, detailing specific compounds and their chemical structures. It outlines the criteria for these substances and emphasizes that any material containing them will be subject to regulation. The bill also updates penalties for trafficking in dangerous substances, including mandatory minimum sentences based on the quantity involved, with increased penalties for substances packaged to appeal to minors. The new legal provisions for xylazine trafficking categorize it as a felony of the first degree, with significant penalties designed to deter such offenses, set to take effect on October 1, 2025.

Statutes affected:
S 1360 Filed: 893.13, 893.135
S 1360 c1: 893.03, 893.135